古汉医药集团股份公司关于控股子公司重大诉讼的公告

Core Viewpoint - The announcement details a significant lawsuit involving a subsidiary of the company, which has filed a civil lawsuit for breach of contract against multiple defendants, seeking the return of contract funds and associated damages [2][4]. Group 1: Lawsuit Details - The lawsuit is currently in the first-instance court stage, with the case number (2026)京0108民初2924, and it has not yet been heard [2]. - The plaintiff is the company's subsidiary, Hunan Qidi Pharmaceutical Bio Co., Ltd., while the defendants include Ningbo Yiduoduo E-commerce Co., Ltd., Fuzhou Letuo Enterprise Management Co., Ltd., and Beijing Tuduo E-commerce Co., Ltd. [5]. - The amount in dispute includes a contract sum of RMB 20 million, along with claims for damages due to fund occupation and related legal fees [3][6]. Group 2: Contractual Background - The plaintiff entered into a product sales contract with the first defendant on February 25, 2022, for a total price of RMB 23.292 million, which has been fully paid, but the defendant failed to deliver the goods as agreed [5]. - The plaintiff is seeking a court order for the return of RMB 20 million and additional compensation for legal fees amounting to RMB 100,000 [6][7]. Group 3: Financial Implications - The company has not yet determined the impact of the lawsuit on its current or future profits due to the uncertainty surrounding the case's outcome [3][8]. - The company has proactively accounted for potential losses by fully provisioning for bad debts related to this lawsuit in its 2024 financial statements [8].